Clinical researchers from the University of Liverpool and King’s College London are investigating the neurological and neuropsychiatric effects of COVID-19.
MQ is supporting this study through the patient and public involvement strategy and supports the joint working of researchers with the PHOSP-COVID study lead by Oxford University.
The COVID-19 Clinical Neuroscience Study (COVID-CNS) will look at 800 UK patients who were admitted to hospital with COVID-19 and had neurological or neuropsychiatric complications, to understand how these problems occur and develop strategies to prevent and treat them.
Project co-lead Dr Benedict Michael, Senior Clinician Scientist Fellow at the University of Liverpool and Consultant Neurologist at The Walton Centre NHS Foundation Trust, said: “COVID-19 patients frequently suffer brain complications during the infection and are left with brain injuries which can have lifelong consequences. Similar problems have been seen in previous pandemics, including Spanish influenza over 100 years ago, but how and why this occurs is remain poorly understood.”
“Without understanding how the virus causes these problems, we are not able to know which existing medications to use or to develop new medications to treat these neurological effects. We’re going to look at cases in detail, exploring clinical data, and laboratory and imaging markers of brain inflammation and injury.”
The project involves more than a dozen research centres from all four nations of the UK and is being led by the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool in collaboration with King’s College London.
Project co-lead Professor Gerome Breen, Professor of Psychiatric Genetics at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, said: “These brain complications of severe COVID-19 infection could cause long terms problems for patients and their families. We want to compare patients with these complications to similarly ill hospitalised patients who did not have these problems. We will monitor their outcomes and integrate social and environmental risk factors into our analyses alongside all the biology information we will measure.”
“This project brings together scientists and clinicians in all four UK nations, across neurology, psychiatry, genetics, epidemiology and immunology. By working together, we aim to rapidly improve our understanding and design better treatments.”
MQ is part of the project’s Patient and Public Involvement Strategy. MQ CEO Lea Milligan says “It is clear from this studies that MQ has been supporting that the impact COVID-19 is having on individuals mental health can be severe. We are pleased to be supporting this new, crucial study. It is only through research that we can understand these after-effects better and even prevent this happening to other people.”
COVID-CNS has been awarded £2.3m by UK Research and Innovation and the Department of Health and Social Care through the UKRI-NIHR COVID-19 Rapid Response Rolling Call.
For more information on the study please visit the COVID-CNS webpage
